Antares Pharma, Inc. (ATRS)Reports Fourth Quarter And Full Year 2013 Operating And Financial Results
3/13/2014 6:48:25 AM
Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the fourth quarter and full year ended December 31, 2013.
•Received approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration (FDA). OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. OTREXUP was launched to rheumatologists in January 2014.
Help employers find you! Check out all the jobs and post your
comments powered by